A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

연구 개요

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.